rosiglitazone has been researched along with isoproterenol in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Forest, C; Franckhauser-Vogel, S; Glorian, M; Robin, D; Robin, P | 1 |
| Antoine, B; Beale, EG; Chauvet, G; Forest, C; Quette, J; Tordjman, J | 1 |
| Bell, D; McDermott, BJ | 1 |
| Cui, N; Jiang, C; Jin, X; Yang, Y; Yu, L | 1 |
| Andersen, ES; Breining, P; Hansen, JB; Isidor, MS; Markussen, LK; Pedersen, SB; Petersen, LI; Rasmussen, NE; Richelsen, B | 1 |
| Chai, BK; Dharmani, DM; Lau, YS; Loong, BJ; Mohankumar, SK; Rais, MM; Ting, KN | 1 |
1 review(s) available for rosiglitazone and isoproterenol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for rosiglitazone and isoproterenol
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes.
Topics: 3T3 Cells; Adipocytes; Adrenergic beta-Agonists; Animals; Clofibrate; Dexamethasone; Enzyme Induction; Fatty Acids; Gene Expression Regulation, Enzymologic; Genes; Glucocorticoids; Hypoglycemic Agents; Isoproterenol; Male; Mice; Phosphoenolpyruvate Carboxykinase (GTP); Protein Biosynthesis; Proteins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 1998 |
Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.
Topics: Adipocytes; Adrenergic beta-Agonists; Animals; Cells, Cultured; Cyclic AMP; Enzyme Activation; Esterification; Fatty Acids; Female; Gene Expression; Glycerol; Glycerol Kinase; Homeostasis; Hypoglycemic Agents; Isoproterenol; Lipid Metabolism; Lipolysis; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Pyruvic Acid; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Viscera | 2003 |
Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy.
Topics: Animals; Cell Survival; Cells, Cultured; Culture Media; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Drug Interactions; Endothelin-1; Glucose; Heart Ventricles; Hypertrophy; Insulin; Insulin-Like Growth Factor I; Isoproterenol; Male; Myocytes, Cardiac; Norepinephrine; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazolidinediones | 2005 |
Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.
Topics: Cell Line; Coronary Vessels; Humans; Hypoglycemic Agents; Isoproterenol; Patch-Clamp Techniques; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2011 |
Characterization of immortalized human brown and white pre-adipocyte cell models from a single donor.
Topics: Adipocytes; Adipose Tissue, Brown; Adipose Tissue, White; Biopsy; Cell Line, Transformed; Colforsin; Humans; Isoproterenol; Neck; Retroviridae; Rosiglitazone; Telomerase; Thermogenesis; Thiazolidinediones; Tissue Donors | 2017 |
Co-administration of conjugated linoleic acid and rosiglitazone increases atherogenic co-efficient and alters isoprenaline-induced vasodilatation in rats fed high fat diet.
Topics: Adrenergic beta-Agonists; Animals; Atherosclerosis; Blood Glucose; Body Weight; Diet, High-Fat; Isoproterenol; Linoleic Acids, Conjugated; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Vasodilation | 2018 |